Developing Truly Clinically Transformative Neuropsychiatric Drugs for Patients in Need

The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics.

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

  • Dive into novel therapeutic approaches for PTSD with AptinyxBionomicsTonix & MAPS 
  • Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics, NeuroRx & Intra-cellular Therapeutics
  • Explore industry approaches for innovative trial design and new methods to modelling the placebo response with NovartisOtsuka & Yale University
  • Hear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA
  • Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern

Uniting 60+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.

Attend the 2020 conference & join your online peers as we battle this unmet need.

2020 Speakers Included:

2020 Partners:

“Excellent conference with a very good and diverse set of speakers and topics”

Jim Cassella, Chief Development Officer, Concert Pharmaceuticals

t t t

“Very good conference”

Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp.

Other Events in the CNS Series: